Form 4: Acadia Pharmaceuticals Director Adora Ndu Boosts Equity Holdings with New Stock Options and RSU Grants

Adora Ndu, a Director at ACADIA PHARMACEUTICALS INC., increased her beneficial ownership through the vesting of restricted stock units and the grant of new stock options and restricted stock units on May 29, 2025.

Summary

• Adora Ndu, a Director of ACADIA PHARMACEUTICALS INC. (ACAD), reported changes in her beneficial ownership of company securities.
• On May 29, 2025, 9,387 restricted stock units (RSUs) vested in full and were converted into 9,387 shares of common stock.
• Following this conversion, Ms. Ndu's direct beneficial ownership of common stock increased to 24,801 shares.
• Additionally, Ms. Ndu was granted 13,793 Director Stock Options with an exercise price of $22.29, expiring on May 28, 2035.
• She also received a grant of 8,107 new Restricted Stock Units.
• The newly granted stock options will vest quarterly over one year, with the final tranche vesting on the earlier of one year from the grant date or the next annual meeting of stockholders.
• The newly granted restricted stock units (8,107 units) will vest in full on the earlier of one year from the grant date or the next annual meeting of stockholders.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director is increasing their equity stake and receiving new incentives, which generally aligns their interests with shareholders and indicates continued commitment to the company.

Positives

• The vesting of 9,387 restricted stock units and the acquisition of common stock increases the director's direct ownership in the company, aligning her interests more closely with shareholders.
• The grant of 13,793 new stock options and 8,107 new restricted stock units indicates continued incentive for the director, reinforcing long-term commitment and performance alignment.

Future Outlook

The document indicates future vesting events for the newly granted 13,793 Director Stock Options and 8,107 Restricted Stock Units. The stock options will vest quarterly over one year, and the RSUs will vest in full on the earlier of one year from the grant date or the next annual meeting of stockholders.

Industry Context

This Form 4 filing reflects standard executive and director compensation practices within the biotechnology and pharmaceutical industries, where equity-based incentives like stock options and restricted stock units are commonly used to align the interests of leadership with long-term shareholder value creation.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and stock options as part of director compensation is a common practice across the biotechnology and pharmaceutical sectors, similar to companies like Biogen Inc. or Gilead Sciences, Inc., which frequently utilize equity awards to incentivize and retain key personnel.
• The vesting schedules, typically over one year or tied to annual meetings, are standard for director equity grants, aiming to provide ongoing alignment without excessively long lock-up periods for non-executive directors.

Stakeholder Impact

• Shareholders: The increase in director equity ownership through RSU conversion and new grants can be viewed positively as it enhances alignment between the director's financial interests and shareholder value.

Next Steps

• The 13,793 Director Stock Options will vest quarterly over one year following the grant date of May 29, 2025, with the final tranche vesting on the earlier of one year from grant or the next annual meeting of stockholders.
• The 8,107 Restricted Stock Units will vest in full on the earlier of one year following the grant date of May 29, 2025, or the next annual meeting of stockholders.

Key Dates

Keywords

ACADIA PHARMACEUTICALS, ACAD, SEC Form 4, Insider Transaction, Director Stock Options, Restricted Stock Units, Equity Compensation, Beneficial Ownership, Biotechnology, Pharmaceuticals